

CITATION REPORT

List of articles citing

Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses

DOI: 10.1097/01.ju.0000028041.27703.da
Journal of Urology, 2002, 168, 1332-6.

Source: <https://exaly.com/paper-pdf/85553522/citation-report.pdf>

Version: 2022-10-03

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
79	Tadalafil in the treatment of erectile dysfunction. <i>Current Urology Reports</i> , 2003 , 4, 472-8	2.8	13
78	[Drug therapy of erectile dysfunction--the current status]. <i>Der Urologe</i> , 2003 , 42, 1322-9		2
77	Tadalafil. <i>Drugs</i> , 2003 , 63, 2203-12; discussion 2213-4	11.5	49
76	Erectile dysfunction: management update. <i>Cmaj</i> , 2004 , 170, 1429-37	3.4	68
75	Therapy of ED: PDE-5 Inhibitors. <i>Endocrine</i> , 2004 , 23, 135-41		24
74	Population dose-response model for tadalafil in the treatment of male erectile dysfunction. <i>Pharmaceutical Research</i> , 2004 , 21, 1463-70	4.3	10
73	Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. <i>Clinical Cardiology</i> , 2004 , 27, 114-19	3.2	49
72	[Erectile dysfunction. Epidemiology, physiology, etiology, diagnosis and therapy]. <i>Der Urologe</i> , 2004 , 43, 197-207; quiz 208-9		2
71	[Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors]. <i>Der Urologe</i> , 2004 , 43, 820-8		9
70	Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. <i>Diabetologia</i> , 2004 , 47, 1914-23	9.9	124
69	Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. <i>Current Urology Reports</i> , 2004 , 5, 467-71	2.8	37
68	Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection. <i>Drugs</i> , 2004 , 64, 1533-45	11.5	15
67	New treatment options for erectile dysfunction in patients with diabetes mellitus. <i>Drugs</i> , 2004 , 64, 2667-1885		62
66	The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 459-68	3.6	18
65	Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. <i>World Journal of Urology</i> , 2005 , 23, 385-92	3.9	37
64	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. <i>World Journal of Urology</i> , 2005 , 23, 374-84	3.9	26
63	Erectile dysfunction: interrelationship with the metabolic syndrome. <i>Current Diabetes Reports</i> , 2005 , 5, 64-9	5.3	31

62	Hypogonadism in the man with erectile dysfunction: what to look for and when to treat. <i>Current Urology Reports</i> , 2005 , 6, 476-81	2.8	16
61	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. <i>Drugs</i> , 2005 , 65, 1621-50	11.5	128
60	Safety and tolerability of oral erectile dysfunction treatments in the elderly. <i>Drugs and Aging</i> , 2005 , 22, 323-38	4.5	5
59	An overview of the diagnosis and treatment of erectile dysfunction. <i>Drugs</i> , 2006 , 66, 2339-55	11.5	17
58	The role of nitric oxide in erectile dysfunction: implications for medical therapy. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 53-62	2.2	108
57	Tadalafil pharmacokinetics in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 280-8	3.6	184
56	Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2007 , 63, 24-35	3.6	46
55	[The basics of phosphodiesterase type 5 (PDE5) inhibition in urology]. <i>Der Urologe</i> , 2008 , 47, 1582-7		3
54	Management of erectile dysfunction in diabetes: an update for 2008. <i>Current Diabetes Reports</i> , 2008 , 8, 437-43	5.3	8
53	Phosphodiesterase 5 inhibition in essential hypertension. <i>Current Hypertension Reports</i> , 2008 , 10, 52-7	4.4	27
52	Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2006 , 60, 812-9	2.8	8
51	Tadalafil in the treatment of erectile dysfunction. <i>Therapeutics and Clinical Risk Management</i> , 2008 , 4, 1315-30	2.7	51
50	[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. <i>Der Urologe</i> , 2009 , 48, 1318, 1320-9		5
49	Efficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis. <i>Asian Journal of Andrology</i> , 2009 , 11, 423-33	2.6	7
48	Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. <i>International Journal of Clinical Practice</i> , 2009 , 63, 27-34	2.8	17
47	Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. <i>International Journal of Clinical Practice</i> , 2010 , 64, 240-55	2.8	108
46	Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. <i>Drug Safety</i> , 2009 , 32, 1-18	4.9	55
45	The effect of tadalafil on anastomotic healing in ischemic small intestine in rats. <i>Surgery Today</i> , 2010 , 40, 555-60	2.9	5

44	Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study. <i>Korean Journal of Urology</i> , 2010 , 51, 647-52		13
43	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. <i>Vascular Health and Risk Management</i> , 2010 , 6, 273-80	4.2	21
42	Effect of tadalafil in chronic renal failure rabbits: relevance to erectile dysfunction. <i>Journal of Zhejiang University: Science B</i> , 2011 , 12, 455-9	4.4	
41	Protective effects of <i>Launaea procumbens</i> on rat testis damage by CCl ₄ . <i>Lipids in Health and Disease</i> , 2012 , 11, 103	4.3	25
40	Therapeutic angiogenesis as a potential future treatment strategy for erectile dysfunction. <i>World Journal of Men's Health</i> , 2012 , 30, 93-8	6.4	3
39	Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. <i>Current Hypertension Reports</i> , 2013 , 15, 475-83	4.4	41
38	Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. <i>Arab Journal of Urology Arab Association of Urology</i> , 2013 , 11, 222-9	1.6	24
37	Erectile dysfunction - an update of current practice and future strategies. <i>Journal of Clinical Urology</i> , 2013 , 6, 210-219	0.2	2
36	Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction. <i>World Journal of Men's Health</i> , 2013 , 31, 83-102	6.4	19
35	Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. <i>World Journal of Men's Health</i> , 2014 , 32, 18-27	6.4	7
34	Management of erectile dysfunction in hypertension: Tips and tricks. <i>World Journal of Cardiology</i> , 2014 , 6, 908-15	2.1	34
33	Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. <i>International Journal of Impotence Research</i> , 2014 , 26, 223-9	2.1	11
32	Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. <i>Nature Reviews Urology</i> , 2014 , 11, 231-41	5.3	26
31	Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse. <i>Scientific Reports</i> , 2015 , 5, 9222	4.7	12
30	Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities. <i>BMC Urology</i> , 2015 , 15, 111	2.1	13
29	Role of sGC-dependent NO signalling and myocardial infarction risk. <i>Journal of Molecular Medicine</i> , 2015 , 93, 383-94	5.3	22
28	The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction. <i>Translational Andrology and Urology</i> , 2016 , 5, 181-6	2.2	6
27	PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 52, 295-302	4.1	24

26	The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. <i>Journal of Urology</i> , 2016 , 196, 715-20	1.5	7
25	Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience. <i>Therapeutic Advances in Urology</i> , 2016 , 8, 249-256	3.1	7
24	The role of the sexual partner in managing erectile dysfunction. <i>Nature Reviews Urology</i> , 2016 , 13, 168-73	3.3	31
23	The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. <i>Journal of Leukocyte Biology</i> , 2017 , 102, 381-391	6.3	42
22	[Erectile dysfunction : Current diagnostics and treatment]. <i>Der Urologe</i> , 2017 , 56, 519-529		9
21	Integrating Sexual Partners into Pharmacological Sex Therapy. 2017 , 453-467		1
20	Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient. <i>Current Cardiology Reports</i> , 2017 , 19, 89	4	15
19	The nitric oxide-guanylate cyclase pathway and glaucoma. <i>Nitric Oxide - Biology and Chemistry</i> , 2018 , 77, 75-87	4.9	27
18	A randomized double-blind, placebo-controlled, cross-over trial assessing the effect of tadalafil (Cialis) on the cardiovascular response in men with complete spinal cord injury above the sixth thoracic level: A Pilot Study. <i>Spinal Cord Series and Cases</i> , 2018 , 4, 105	1.3	2
17	Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs. <i>Pharmaceutics</i> , 2018 , 10,	6	7
16	Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction. <i>Sexual Medicine</i> , 2019 , 7, 282-291	2.6	7
15	Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: a comparative randomized prospective study. <i>International Urology and Nephrology</i> , 2019 , 51, 1491-1499	2.2	1
14	Increased bioavailability of cyclic guanylate monophosphate prevents retinal ganglion cell degeneration. <i>Neurobiology of Disease</i> , 2019 , 121, 65-75	7.1	6
13	A prospective study of the effect of antihypertensive medications on the sexual functions of hypertensive adult male patients. <i>Future Science OA</i> , 2020 , 6, FSO479	2.6	2
12	Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review. <i>International Journal of Retina and Vitreous</i> , 2020 , 6, 38	2.8	5
11	The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts. <i>Journal of Clinical Medicine</i> , 2020 , 9,	4.9	4
10	Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , 2006 , 1, 439-49	3.8	9
9	Sexual function in hypertensive patients receiving treatment. <i>Vascular Health and Risk Management</i> , 2006 , 2, 447-55	4.2	30

8	Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease. <i>Korean Journal of Internal Medicine</i> , 2007 , 22, 37-9	2.5	4
7	Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. <i>Asian Journal of Andrology</i> , 2016 , 18, 723-31	2.6	8
6	Human tissue kallikrein-1 protects against the development of erectile dysfunction in a rat model of hyperhomocysteinemia. <i>Asian Journal of Andrology</i> , 2019 , 21, 508-515	2.6	4
5	Current use of phosphodiesterase inhibitors in urology. <i>Turkish Journal of Urology</i> , 2015 , 41, 88-92	1.2	9
4	PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy. <i>Reviews in Urology</i> , 2005 , 7 Suppl 2, S33-8	1	2
3	Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 139-48	6.2	29
2	Testosterone replacement therapy and erectile dysfunction.. <i>International Journal of Impotence Research</i> , 2022 ,	2.1	
1	Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study.. <i>Diabetology and Metabolic Syndrome</i> , 2022 , 14, 56	5.4	